Sciele Pharma Inc. v. Lupin Ltd.
684 F.3d 1253
Fed. Cir.2012Background
- Lupin filed an ANDA to market a generic Fortamet and alleged noninfringement and invalidity of Shionogi’s ’866 patent under 35 U.S.C. § 271(e)(2)(A).
- Shionogi asserted claims 1, 3, 4, 5, and 25, with claim 3 limited to a T max of 7 hours and the others at 7.5 hours.
- The district court granted a preliminary injunction prohibiting Lupin from selling the generic during the litigation period.
- The court found likelihood of infringement based largely on Lupin’s proposed labeling, and deferred ruling on obviousness but noted the heavy burden of validity given the PTO’s role.
- We vacated and remanded for an independent obviousness analysis, emphasizing Lupin’s arguments based on Cheng and Timmins and the prosecution history.
- On remand, the district court reaffirmed Lupin’s lack of obviousness defenses under a deferred-to-PTO framework, leading to appeal and our review of an abuse of discretion standard.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Presumption of validity and burden of proof | Lupin argues presumption should be undermined due to erroneous issuance and PTO handling. | Shionogi argues presumption remains and the burden is heightened by PTO involvement. | Presumption of validity applies; clear and convincing standard remains. |
| Whether the district court misapplied obviousness standard given prosecution history | Lupin contends Cheng and Timmins, viewed with prosecution history, render claims obvious. | Shionogi contends lack of motivation to combine Cheng and Timmins and improper use of prosecution history. | District court erred; substantial question of validity exists. |
| Role of Cheng and Timmins in establishing obviousness | Combination of Cheng (8–12 hour T max) with Timmins (mean T max lower range) renders a lower T max obvious. | Shionogi disputes the motivation and argues Timmins does not disclose mean T max identical to claimed range. | Timmins teaches lowering T max; combination with Cheng raises substantial validity question. |
| Effect of PTO consideration on obviousness analysis under KSR | Because prior art was before PTO, the defense should be differently weighed under KSR. | PTO consideration does not alter the standard of proof or the weight of evidence. | KSR applied; prior PTO consideration affects weight, not the standard; still supports substantial question. |
Key Cases Cited
- Amazon.com, Inc. v. Barnesandnoble.com, Inc., 239 F.3d 1343 (Fed. Cir. 2001) (four-factor test for a preliminary injunction)
- i4i Ltd. P'ship v. Microsoft Corp., 131 S. Ct. 2238 (U.S. Supreme Court, 2011) (clear and convincing standard; no heightened burden due to PTO)
- Graham v. John Deere Co. of Kansas City, 383 U.S. 1 (U.S. Supreme Court, 1966) (framework for obviousness analysis under §103)
- KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398 (U.S. Supreme Court, 2007) (flexible, expansive obviousness standard)
- Pharmastem Therapeutics, Inc. v. Viacell, Inc., 491 F.3d 1342 (Fed. Cir. 2007) (deference to PTO in validity determinations)
- Abbott Labs. v. Sandoz, Inc., 566 F.3d 1282 (Fed. Cir. 2009) (abuse of discretion standard for injunction rulings)